We produce cutting-edge pharmaceutical software for fully autonomous de novo drug design and screening.

Our user-friendly platform gives researchers access to state-of-the-art deep learning tools to drastically reduce the timeline, costs, and failure rates of early-stage drug development.

Moving Forward…

In a market where entities such as Schrodinger have set the bar, we've observed the limitations of this approach including: growth stagnation, increasing operational costs without proportional returns, and reduced profitability.

We aim to expand our software's capabilities to meet the multifaceted needs of this process, leveraging advanced R&D in artificial intelligence, substantial computational resources, and extensive laboratory data.

Through this strategy, we will pave the way for the continuous enhancement of our offerings, ensuring we remain at the forefront of innovation and service in the drug discovery sector.

Our vision is to evolve beyond the current paradigm of focusing solely on designing "hit" compounds without the extensive use of molecular optimization and predictive modeling.

Our commitment is to transform into a comprehensive solution provider, addressing a broad spectrum of challenges in drug discovery.

This data not only trains our models but also validates them, ensuring our solutions are grounded in real-world applications. By actively engaging in the drug discovery journey, we will gain firsthand insights into the most valuable features our clients need, avoiding assumptions and truly meeting their needs.